"Janus Kinase 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.
| Descriptor ID |
D053614
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.124.200 D12.776.476.393.200 D12.776.624.664.700.117
|
| Concept/Terms |
Janus Kinase 2- Janus Kinase 2
- JAK-2 Protein Tyrosine Kinase
- JAK 2 Protein Tyrosine Kinase
- JAK2 Protein Tyrosine Kinase
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase 2".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase 2".
This graph shows the total number of publications written about "Janus Kinase 2" by people in this website by year, and whether "Janus Kinase 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 2 | 2 |
| 2007 | 8 | 3 | 11 |
| 2008 | 8 | 1 | 9 |
| 2009 | 4 | 2 | 6 |
| 2010 | 3 | 0 | 3 |
| 2011 | 5 | 2 | 7 |
| 2012 | 2 | 2 | 4 |
| 2013 | 0 | 2 | 2 |
| 2014 | 6 | 4 | 10 |
| 2015 | 3 | 1 | 4 |
| 2016 | 3 | 3 | 6 |
| 2017 | 3 | 4 | 7 |
| 2018 | 4 | 0 | 4 |
| 2019 | 2 | 0 | 2 |
| 2020 | 3 | 1 | 4 |
| 2021 | 2 | 1 | 3 |
| 2022 | 1 | 3 | 4 |
| 2023 | 0 | 3 | 3 |
| 2024 | 3 | 2 | 5 |
| 2025 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Janus Kinase 2" by people in Profiles.
-
JAK2/JAK2V617F heterodimers activate STAT1 and AhR to promote thrombocytosis. J Exp Med. 2025 Dec 01; 222(12).
-
Modulation of the JAK2-STAT3 pathway promotes expansion and maturation of human iPSC-derived myogenic progenitor cells. Stem Cell Reports. 2025 Nov 11; 20(11):102692.
-
Loss of Socs2 improves molecular responses to IFNa in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F. Leukemia. 2025 Apr; 39(4):876-887.
-
Leukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosis. Proc Natl Acad Sci U S A. 2024 Dec 10; 121(50):e2401899121.
-
Loss of Dnmt3a increases self-renewal and resistance to pegIFN-a in JAK2-V617F-positive myeloproliferative neoplasms. Blood. 2024 06 13; 143(24):2490-2503.
-
Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity. J Med Chem. 2024 06 27; 67(12):10012-10024.
-
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN. Blood Adv. 2024 05 14; 8(9):2312-2325.
-
IL-1? promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells. Blood Adv. 2024 03 12; 8(5):1234-1249.
-
Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis. Nat Commun. 2023 10 12; 14(1):6414.
-
Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. Blood. 2023 04 27; 141(17):2127-2140.